Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / Jan / Crossing the Rubicon
Business & Regulation Clinical Trials Advanced Medicine Cell & Gene Sponsored

Crossing the Rubicon

What does the controversial genome editing work of Jiankui He mean for biomedical research?

By Maryam Mahdi 01/08/2019 0 min read Quick Read (pre 2022)

Share

A scientist has received international condemnation in the genetics field after claiming to have produced the world’s first gene-edited babies using CRISPR technology. In videos posted by his lab to justify the work, Jiankui He, an Associate Professor at the Southern University of Science and Technology in Shenzhen, China, says the gene-edited twin girls were born as “healthy as any other babies” (1). The gene editing was conducted after IVF, when each embryo was just a single cell, to modify the CCR5 gene to block HIV infection. The girls’ father was HIV positive and He says that the twins will be monitored over the course of the next 18 years.

“I understand my work will be controversial, but I believe families need this technology and I’m willing to take the criticism for them,” He said in one of the videos. He says he targeted HIV because of “safety”, adding that CCR5 is one of the best studied genes and many people have natural genetic variation that disables the gene to prevent HIV infection. He claims it was the “simplest gene surgery possible.” Gene editing to correct broken genes to perhaps target familial cancers or muscular dystrophy would be more complex.

CRISPR’s ability to edit genes, coupled with its cost-efficient production and high degree of fidelity, make it an attractive method of genome editing, but navigating the ethical minefield associated with its use seems to be challenging for the research community. The risk of harm to human life and its potential to cause environmental damage limit its applications. Current iterations of the technology make it possible to introduce off-target mutations (which introduce mosaicism and off-target mutations (which can be deleterious) into human DNA. Forty countries including the UK, US and China have banned or discouraged the use of genome editing.

Gaetan Burgio, Geneticist and Group Leader at Australian National University, who tweeted about a panel discussion that He was involved in at the Human Genome Editing Summit where he discussed the work, said that the method He outlined doesn’t do enough to rule out mosaicism or deletions (2). The scientific community has called for an independent peer-review of the trial to assess the validity of the claims made by He.

The global scientific community fears He’s work could hinder the future of CRISPR by exacerbating the public’s scepticism and forcing the hand of regulators, compelling them to put even stricter rulings into place about the use of the technology.

The Southern University of Science and Technology says it was not aware of the project and that He had been on paid leave since February. A variety of mixed reports are now circling in the media regarding He’s location. Some have reported he is under house arrest in China, but the Southern University of Science and Technology says that this information is not accurate. China’s Vice Minister for Science and Technology has called for a suspension of any scientific activities by those involved in He’s work.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. YouTube, “The He Lab” (2018). Available at https://bit.ly/2PU7doi. Last accessed December 5, 2018. Twitter, @GaetanBurgio (2018). Available at https://bit.ly/2TRKbwu. Accessed December 3, 2018.

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

The (Un)fairer Sex?
Clinical Trials
The (Un)fairer Sex?

November 6, 2014

0 min read

Our understanding of the differences in male and female biology is constantly growing – but can we translate that knowledge into better healthcare for all?

Sex Matters
Clinical Trials
Sex Matters

November 6, 2014

0 min read

New NIH policies aim to correct the sex bias in preclinical research

Asking the Right Questions in R&D
Clinical Trials Contract Development Services Trends & Forecasts
Asking the Right Questions in R&D

March 6, 2025

3 min read

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

AI, Big Data, and Digital Disruption
Digital Technologies Clinical Trials
AI, Big Data, and Digital Disruption

March 31, 2025

7 min read

An industry survey looks at changing attitudes and challenges in digital innovation for clinical research. Uptake is slow but steady.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.